GlassScriptPhysician profile
Husam Nayef
NPI 1831505528
$23,951.02
in general payments reported to CMS, 2019-2025
19 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.04 · 2021: $374 · 2022: $449 · 2023: $16K · 2024: $6,460 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $19K · Travel and Lodging: $2,476 · Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $18,500.00 |
| Travel and Lodging | $2,475.87 |
| Food and Beverage | $2,129.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $21,254.00 | 2023-2025 | Da Vinci Surgical System, Ion |
| Pulmonx Corporation | $560.60 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $416.22 | 2021-2024 | Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $306.10 | 2024-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $291.16 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $209.77 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $187.97 | 2022-2024 | Tyvaso, Remodulin |
| Amgen INC. | $121.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $113.92 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $94.23 | 2023-2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $93.85 | 2022 | |
| Jazz Pharmaceuticals INC. | $79.61 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.21 | 2024-2025 | Ofev |
| Pinnacle Biologics, INC | $47.11 | 2025 | Photofrin |
| Abbvie INC. | $30.77 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $30.18 | 2024 | |
| Mylan Specialty L.P. | $23.06 | 2024 | Yupelri |
| Genentech USA, INC. | $22.04 | 2020 | |
| Electromed, INC. | $18.30 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Nayef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.